GLPwatch
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
NCT06874751 · Completed
Last updated 2026-05-28This study is testing whether the medication semaglutide reduces the risk of heart-related events in adults who are overweight or obese and have existing heart disease.
Status Completed The study has finished.
Type Observational
Participants 45,456 people
Who can join Ages 45+ · all sexes
Timeline Started 2024-12 · est. completion 2025-03
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT06874751 ↗
Description as written by the study sponsor.
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.
Treatments tested
- No treatment given Other
No treatment given
- No treatment given Other
No treatment given
| Main thing measured | Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD) |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06874751 ↗